Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTSC | P53634 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7587101 | 1.00 | CTSS (0.54) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL30051602 | 1.00 | CTSS (0.54) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL29789610 | 0.97 | CTSL (0.52) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL30805357 | 0.96 | CTSL (0.51) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL29385523 | 0.96 | CTSL (0.51) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL6828134 | 0.93 | OPRD1 (0.52) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL7042469 | 0.93 | OPRD1 (0.52) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL7211697 | 0.93 | OPRD1 (0.52) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL29867736 | 0.92 | QRFPR (0.53) | CTSSCTSLCTSBMMEACE | |
| SCHEMBL21437346 | 0.92 | OPRD1 (0.51) | CTSSCTSLCTSBMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080142-A | Polypeptide for cancer targeted therapy and corresponding drug/fluorescent dye conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122080119-A | Synthesis method of MC-Gly-Gly-Phe-Gly tetrapeptide linker | — | 2026-05-26 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | claimed |
| EP-4720127-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| CN-115279417-A | Bioactive substance conjugate and preparation method and application thereof | 苏州宜联生物医药有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-11446292-B2 | Compounds and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2022-09-20 | — | — | US | claimed |
| EP-4045087-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2022-08-24 | — | — | EP | claimed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | claimed |
| US-20220249682-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2022-08-11 | — | — | US | claimed |
| CN-114845739-A | Drug conjugate of eribulin derivative, preparation method and application thereof in medicine | 上海森辉医药有限公司 | 2022-08-02 | — | — | CN | claimed |
| US-20220211863-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2022-07-07 | — | — | US | claimed |
| CN-112604004-B | Anti-human EGFR antibody drug conjugate and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-05-10 | — | — | CN | claimed |
| EP-3010532-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | University of North Carolina at Pembroke (US) | 2016-04-27 | — | — | EP | claimed |
| WO-2014204956-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2014-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSS 1516/4885CTSL 108/4885CTSB 1507/4885 |
| US-20220211863-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | CTSS 2807/4885CTSL 1963/4885CTSB 2121/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | CTSS 2817/4885CTSL 2372/4885CTSB 2858/4885 |
| US-11446292-B2 | Compounds and conjugates thereof | TOP2A, TOP1, TOP2B | CTSS 2807/4885CTSL 1963/4885CTSB 2121/4885 |
| US-20220249682-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | PDCD1LG2, CD274, PDCD1 | CTSS 1712/4885CTSL 150/4885CTSB 1509/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | CTSS 3147/4885CTSL 727/4885CTSB 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.